Stock Scorecard

Stock Summary for Polypid Ltd (PYPD) - $3.31 as of 6/19/2025 8:33:47 AM EST

Total Score

7 out of 30

Safety Score

10 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PYPD

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PYPD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PYPD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PYPD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PYPD (10 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for PYPD

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - PolyPid ( NASDAQ:PYPD ) 6/16/2025 11:20:00 PM
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results 6/16/2025 11:20:00 PM
PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention 6/11/2025 1:42:00 PM
PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention 6/11/2025 1:39:00 PM
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial - PolyPid ( NASDAQ:PYPD ) 6/9/2025 4:53:00 PM
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - PolyPid ( NASDAQ:PYPD ) 6/9/2025 12:54:00 PM
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Circle Internet Group ( NYSE:CRCL ) , Davis Commodities ( NASDAQ:DTCK ) 6/9/2025 12:46:00 PM
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - PolyPid ( NASDAQ:PYPD ) 6/9/2025 11:30:00 AM
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 6/6/2025 8:05:00 PM
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 - PolyPid ( NASDAQ:PYPD ) 6/6/2025 8:05:00 PM

Financial Details for PYPD

Company Overview
Ticker PYPD
Company Name Polypid Ltd
Country USA
Description PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Sector Name LIFE SCIENCES
Industry Name SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 3.31
Price 4 Years Ago 172.20
Last Day Price Updated 6/19/2025 8:33:47 AM EST
Last Day Volume 343,221
Average Daily Volume 909,160
52-Week High 4.49
52-Week Low 2.30
Last Price to 52 Week Low 43.91%

Valuation Measures
Trailing PE N/A
Industry PE 38.16
Sector PE 40.43
5-Year Average PE -18.22
Free Cash Flow Ratio 15.05
Industry Free Cash Flow Ratio 35.72
Sector Free Cash Flow Ratio 31.51
Current Ratio Most Recent Quarter 0.71
Total Cash Per Share 0.22
Book Value Per Share Most Recent Quarter 0.01
Price to Book Ratio 392.23
Industry Price to Book Ratio 5.06
Sector Price to Book Ratio 30.07
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 5.83
Sector Price to Sales Ratio Twelve Trailing Months 34.41
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 10,190,900
Market Capitalization 33,731,879
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -21.61%
Reported EPS 12 Trailing Months -3.98
Reported EPS Past Year -0.70
Reported EPS Prior Year -4.91
Net Income Twelve Trailing Months -30,842,000
Net Income Past Year -29,022,000
Net Income Prior Year -23,865,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 2,272,000
Total Cash Past Year 15,641,000
Total Cash Prior Year 5,609,000
Net Cash Position Most Recent Quarter 1,891,000
Net Cash Position Past Year 15,007,000
Long Term Debt Past Year 634,000
Long Term Debt Prior Year 6,379,000
Total Debt Most Recent Quarter 381,000
Equity to Debt Ratio Past Year 0.92
Equity to Debt Ratio Most Recent Quarter 0.18
Total Stockholder Equity Past Year 7,684,000
Total Stockholder Equity Prior Year -2,096,000
Total Stockholder Equity Most Recent Quarter 86,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 0
Free Cash Flow Per Share Twelve Trailing Months 0.00
Free Cash Flow Past Year -22,039,000
Free Cash Flow Prior Year -17,432,000

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.18
MACD Signal 0.15
20-Day Bollinger Lower Band 2.39
20-Day Bollinger Middle Band 2.89
20-Day Bollinger Upper Band 3.40
Beta 1.25
RSI 59.45
50-Day SMA 14.42
150-Day SMA 0.00
200-Day SMA 55.38

System
Modified 6/19/2025 8:33:48 AM EST